DeCure for Neurodevelopmental disorder with language delay and seizures
DeCure's autonomous Neuro AI scientist is researching a drug-repurposing hypothesis for neurodevelopmental disorder with language delay and seizures — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleNeurodevelopmental disorder with language delay and seizures maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for neurodevelopmental disorder with language delay and seizures is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
TIAM Rac1 associated GEF 1 (TIAM1) — TIAM1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet apo structuredrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 4K2P · 1.98 Å · ligand none (apo structure). Experimental structure, not a prediction.
What the evidence adds up to
Developmental language disorder affects 3% to 7% of preschoolers, with male sex a consistent risk factor. Twin and family aggregation studies confirm genetic contributions, but genes alone do not determine outcomes. Sex chromosome trisomies provide a model for the link between genetic alteration and language disorder. The condition is often hidden, going undetected for years until academic or behavioural problems emerge, and its presentation shifts across the lifespan.
A 5½-year-old boy with language delay, behavioural problems, and pervasive developmental disorder had frequent generalised spike and polyspike activity on EEG. After therapeutic anticonvulsant levels were reached, communication skills and behaviour improved, as did the EEG. The authors note that response of language dysfunction to anticonvulsants has been generally disappointing in previously reported cases of communication disorders with EEG abnormalities, but a trial is probably warranted.
A separate case report describes an 8-year-old boy who was non-verbal at age three, had seizures at 15 months, and was prescribed Ritalin, which caused loss of appetite followed by overeating and obesity without good effect. A new unnamed medication was started in December 2022, after which he was able to speak and form sentences. The report claims this medication activated more brain regions related to speech and triggered rearrangement of neuronal DNA, but provides no sample size, control group, or drug name.
Two Iranian siblings with a biallelic likely pathogenic NRDC gene variant had developmental delay, microcephaly, hypotonia, seizures, and absent speech. This is the second report linking biallelic NRDC variants to neurodevelopmental disorders. What remains missing are controlled trials of any medication for language delay in this population, clear patient stratification by EEG abnormality or genetic subtype, and funding for studies that move beyond single case reports.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Journal of Neuroscience Research · 2021 · 59 citations
Sex differences in early language delay and in developmental language disorder
AbstractDevelopmental language disorder (DLD) is a neurodevelopmental condition, occurring in about 3% to 7% of preschoolers, that can impair communication and negatively impact educational and social attainments, in spite of adequate neurological, cognitive, emotional, social development, and educational opportunities for language learning. Significant risk factors for DLD are male sex, familial history of early language delay, low parental education, and various perinatal factors. A strong sex effect with a higher prevalence of language delay and DLD in males than in females has been consistently reported. Neurobiological and environmental risk factors, interacting with each other, are probably responsible for the phenotypic expression of DLD. The aim of this brief review is to further the knowledge of the role of sex in early language delay and DLD by analyzing the evidence from four significant sources: epidemiological studies, studies on twins, family aggregation studies, and studies on sex chromosome trisomies. Data pertaining only to sex differences (biological and physiological characteristics of females and males) will be analyzed. Studies on family aggregations and twins confirm the role of genetic factors and of sex in determining language abilities and disabilities, but genes alone do not determine outcomes. Sex chromosome trisomies represent a unique example of the relationship between a genetic alteration and a language disorder. Clarification of how sex acts in determining DLD could provide new information on early risk factors and, thus, contribute to improve diagnosis and clinical management.
Acquired Aphasia With Convulsive Disorder: A Pervasive Developmental Disorder Variant
AbstractA 5 1/2-year-old boy with language delay and behavioral problems was evaluated. His symptoms were consistent with pervasive developmental disorder, and electroencephalography showed frequent generalized spike and polyspike activity. After therapeutic levels of anticonvulsant medication were achieved, improvement was noted in communication skills and behavior, as well as on the electroencephalogram. Although the response of language dysfunction to these drugs has been generally disappointing in previously reported cases of communication disorders associated with electroencephalographic abnormalities, a trial of anticonvulsant medication is probably warranted.
Journal of Child Psychology and Psychiatry · 2025 · 5 citations
Annual Research Review: Developmental language disorder – a hidden condition with lifelong impact
AbstractDevelopmental language disorder (DLD) is one of the most common neurodevelopmental disorders. Yet, it is a hidden disorder: it can go undetected for years and may not be uncovered until academic, behavioral, and/or mental health challenges begin to surface. In this review, we survey what is currently known about DLD across the lifespan, with a particular focus on its collateral effects in childhood and adulthood. We begin with a brief discussion of terminological issues that have contributed to the confusion about and lack of awareness of DLD. We then describe the development of DLD from infancy through adulthood, the ways in which its presentation shifts over time and with transitions to new developmental tasks and contexts, and some of the significant associated challenges outside of the language domain that are often faced by people with DLD. Next, we review current scientific knowledge about the neurobiological and genetic bases of DLD. In the final section, we provide an overview of some of the current best practices for screening and assessment and approaches to intervention for children, adolescents, and adults. We conclude by reflecting on challenges and opportunities for future research and offering some recommendations for clinical practice, particularly for mental health practitioners.
EPILEPTIFORM ABNORMALITIES IN PATIENTS WITH DEVELOPMENTAL LANGUAGE IMPAIRMENT
AbstractObjectives: Developmental language impairment (DLI) is a developmental disorder of language not associated with global developmental delay. Electroencephalograms (EEG) are frequently performed on these children to rule out possible epileptic abnormalities and underlying etiologies. The objective of this study was to determine the proportion and type of EEG abnormalities in patients with DLI and compare this to a previously published control cohort.
Medical and Clinical Case Reports · 2024 · 0 citations · open access
New Medication to Treat Speech Delay
AbstractBackground: Delay in language development, social communication, play skills, and behavior in kids can be attributed to a variety of factors. One common cause is genetic predisposition [1], as children with a family history of language or developmental delays are more likely to experience similar challenges themselves. Additionally, neurological factors such as brain injury or abnormalities such as Seizures can impact a child's ability to develop language and social skills [2,3,4]. The most common and effective treatments available include speech therapy, social skills training, occupational therapy and play therapy, which help children improve their abilities. However, none of these treatments are definitive. Case Presentation: Here, we present a child who is currently 8 years old. At the age of three years and one month, Soren is a boy and he was evaluated in a clinic in Australia due to problems such as inability to establish verbal communication. The results of the evaluation showed concerns about the development of speech skills, social communication, behavioral skills, and playing. At the age of three years and one month, he was largely non-verbal and had significant speech impairments. Consulting and evaluation led to the conclusion that he needed speech therapy, occupational therapy, play therapy, and psychological counseling. Additionally, Ritalin medication was prescribed for him .According to his mother's statement, it did not have a good effect on him and only caused a loss of appetite followed by overeating and obesity in the child. In this case, we started a new medication for him once a day. We began this medication in December 2022, and the results were remarkable. He is now able to speak and form sentences. Let's talk a little bit about Soren's progress. Conclusion: The inability to speak in children can have various causes such as genetic factors, brain impairments, etc. We examined a child who had experienced a lack of progress in speech and behavioral skills, and had also suffered from seizures at the age of fifteen months. A new medication was prescribed for him, which led to a significant improvement in his verbal communication and considerable progress in his behavioral skills. We believe that this medication has been able to activate more parts of the brain related to speech. Furthermore, with the use of this medication, it triggered the rearrangement of the neuronal DNA related to speech, enabling the child to speak.
American Journal of Medical Genetics Part A · 2025 · 0 citations
Biallelic Variant in <scp> <i>NRDC</i> </scp> Gene in Two Siblings With Developmental Delay and Seizures
AbstractWe report a biallelic likely pathogenic variant in the NRDC gene in two Iranian siblings with developmental delay, microcephaly, hypotonia, seizures, and absent speech. Exome sequencing (ES) identified a frameshift deletion in exon 15 of NRDC (NM_001101662.2): c.1702_1703del (p.Met568Valfs*2), confirmed to segregate with disease in the family. This is the second report implicating biallelic NRDC gene variants in neurodevelopmental disorders. Our findings expand the phenotypic spectrum and support a potential role for NRDC in severe neurodevelopmental delay.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
